SRNE - ソレント・セラピュ―ティクス (Sorrento Therapeutics Inc.)

SRNEのニュース

   Financial Review: Sorrento Therapeutics (NASDAQ:SRNE) & Alector (NASDAQ:ALEC)  2021/11/04 05:24:42 Dakota Financial News
Sorrento Therapeutics (NASDAQ:SRNE) and Alector (NASDAQ:ALEC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability. Profitability This table compares Sorrento Therapeutics and Alectors net margins, return on equity and return on assets. []
   Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Expected to Post Quarterly Sales of $10.21 Million  2021/11/04 04:30:41 Dakota Financial News
Wall Street brokerages expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report $10.21 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Sorrento Therapeutics earnings. The lowest sales estimate is $3.51 million and the highest is $16.90 million. Sorrento Therapeutics reported sales of $11.75 million in the same quarter []
   Sorrento Therapeutics Inc. (NASDAQ: SRNE) Analysts Prediction On How Much It Could Rise  2021/11/03 11:30:00 Stocks Register
The trading price of Sorrento Therapeutics Inc. (NASDAQ:SRNE) closed lower on Tuesday, November 02, closing at $6.95, -1.42% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
   Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer  2021/11/01 13:00:00 Intrado Digital Media
SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee''s Pharmaceutical Holdings Limited (Lee''s Pharma, HKEX: 950) has submitted a NDA (new drug application) for the anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory to treat recurrent or metastatic cervical cancer. The NDA application has been accepted by China NMPA.
   -$0.21 Earnings Per Share Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter  2021/10/28 16:03:34 Dakota Financial News
Equities research analysts expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report earnings of ($0.21) per share for the current quarter, according to Zacks. Two analysts have made estimates for Sorrento Therapeutics earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.17). Sorrento Therapeutics posted earnings per share of []
   Sorrento Therapeutics forms Mexico subsidiary in COVID-19 product development push  2021/07/20 19:49:49 Seeking Alpha
   Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento''s Portfolio of COVID-19 Products in Mexico and Parts of Latin America  2021/07/20 19:29:06 Benzinga
Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico. Sorrento''s Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units. Sorrento Therapeutics Mexico will coordinate all activities required for commercialization of COVI-STIX, and for the clinical trials and registration of Sorrento''s portfolio of products for the Mexican and potentially other Latin American Markets. SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE , ", Sorrento", )) today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico ("Sorrento Mexico"), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories. Sorrento Mexico has established offices in Mexico City with Dr.
   Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrentos Portfolio of COVID-19 Products in Mexico and Parts of Latin America  2021/07/20 19:29:00 Intrado Digital Media
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (Sorrento Mexico), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.
   Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management  2021/07/20 16:53:00 Intrado Digital Media
PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced complete enrollment of SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica. SP-102 has received Fast Track status from the FDA.
   Sizing Up Sorrento Therapeutics. AGAIN  2021/07/18 19:35:44 Seeking Alpha
   Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma  2021/04/27 18:30:35 Benzinga
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE ) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI-3031 is based on Sorrento's G-MAB library that has fostered the development of several oncology programs currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently … Full story available on Benzinga.com
   Why Sorrento Therapeutics' Stock Is Trading Higher Today  2021/04/27 17:09:50 Benzinga
Sorrento Therapeutics (NASDAQ: SRNE ) shares are trading higher … Full story available on Benzinga.com
   B.Riley Financial Stick to Their Buy Rating for Sorrento Therapeutics By Investing.com  2021/04/23 06:35:01 Investing.com
B.Riley Financial Stick to Their Buy Rating for Sorrento Therapeutics
   Time to Join Sorrento Therapeutics on its Next Leg Up  2021/04/20 15:15:00 Entrepreneur
We've heard from Sorrento Therapeutics (NASDAQ:SRNE) before, and usually, things are looking good for the biotechnology industry firm. While it's never been a big player—share prices haven't broken the $15 price point in the last five years
   Sorrento's Human Derived Mesenchymal Stem Cells Achieves 100% Discharge Rate In Critically-Ill COVID-19 Patients  2021/04/20 13:51:28 Benzinga
Sorrento Therapeutics Inc (NASDAQ: SRNE ) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS). The study met its primary objective to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells … Full story available on Benzinga.com

calendar